Are the Newer Antidepressant Drugs as Effective as Established Physical Treatments? Results from an Australasian Clinical Panel Review
- 1 December 1999
- journal article
- research article
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
- Vol. 33 (6) , 874-881
- https://doi.org/10.1046/j.1440-1614.1999.00648.x
Abstract
Objective: The aim of this study was to determine, in a clinical panel sample, the extent to which patients with depression (and melancholic and non-melancholic subtypes) judged the effectiveness of previously received antidepressant treatments, particularly the comparative effectiveness of the older and newer antidepressant drugs. Method: Twenty-seven Australasian psychiatrists assessed 341 non-psychotic depressed patients and rated the extent to which previous antidepressant treatments had been effective. Patients were assigned to ‘melancholic’ and residual ‘non-melancholic’ categories by two processes (DSM-IV decision rules, and a cluster analysis-derived allocation) and treatment effectiveness examined within each category. Results: Electroconvulsive therapy (both bilateral and unilateral) was judged as highly effective by both melancholic and non-melancholic patients. Antipsychotic medication similarly rated highly (but was judged as more effective by the non-melancholic than melancholic patients). The tricyclics and irreversible monoamine oxidase inhibitors (MAOIs) were rated as more effective by the whole sample than several newer antidepressant classes (including the selective serotonin re-uptake inhibitors [SSRIs], venlafaxine, mianserin and moclobemide), whether effectiveness was examined dimensionally or categorically. Comparison of the overall tricyclic and SSRI classes indicated that any superior tricyclic effectiveness was specific to the melancholic subjects. Conclusions: Despite methodological limitations intrinsic to such clinical panel data, the judged greater effectiveness of the older antidepressants (tricyclics and irreversible MAOIs) for melancholic depression is of importance. If valid, such data are of intrinsic clinical relevance but also have the potential to inform us about the neurobiological determinants of ‘melancholia’ and pharmacological actions which contribute to its effective treatment.Keywords
This publication has 13 references indexed in Scilit:
- Treatment Research at the Crossroads: The Scientific Interface of Clinical Trials and Effectiveness ResearchAmerican Journal of Psychiatry, 1999
- Major depressive subtypes and treatment responseBiological Psychiatry, 1997
- Melancholia: A Disorder of Movement and MoodPublished by Cambridge University Press (CUP) ,1996
- Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholiaAmerican Journal of Psychiatry, 1994
- Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter studyJournal of Affective Disorders, 1993
- Melancholic/endogenous depression and response to somatic treatment and placeboAmerican Journal of Psychiatry, 1992
- Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter studyJournal of Affective Disorders, 1990
- A Treatment Outline for Depressive DisordersAustralian & New Zealand Journal of Psychiatry, 1983
- Unprosecuted Mentally Abnormal OffendersBMJ, 1965
- Drug therapy in depressions: Controlled evaluation of imipramine, isocarboxazide, dextroamphetamine‐amobarbital, and placeboClinical Pharmacology & Therapeutics, 1962